CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 140 enrolled
Drug / intervention
Folic Acid +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00611806
NCT00611806Phase 4Completed
CompareCT.gov

A Placebo-Controlled Trial of Folate With B12 in Schizophrenia Patients With Residual Symptoms

Massachusetts General Hospital·interventional·Posted Feb 11, 2008·Updated Aug 19, 2014

In Brief

A Phase 4 clinical trial evaluating Folic Acid, B12, and 1 other intervention for Schizophrenia. Completed, enrolled 140 participants across 3 sites.

Detailed Summary

This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2008
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.4 years ago

Interventions

Folic Aciddietary

Folic acid 2mg po daily

B12dietary

B12 400 micrograms po daily

Placeboother

1 capsule po daily